• 1
    Tubiana M, Milhaud G, Coutris G, Lacour J, Parmentier C, Bok B. Medullary carcinoma and thyrocalcitonin. BMJ. 1968; 4: 87-89.
  • 2
    Machens A, Schneyer U, Holzhausen HJ, Dralle H. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab. 2005; 90: 2029-2034.
  • 3
    Fialkowski E, DeBenedetti M, Moley J. Long-term outcome of reoperations for medullary thyroid carcinoma. World J Surg. 2008; 32: 754-765.
  • 4
    Bergholm U, Bergstrom R, Ekbom A. Long-term follow-up of patients with medullary thyroid carcinoma of the thyroid. Cancer. 1997; 79: 132-138.
  • 5
    Modigliani E, Cohen R, Campos JM, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. Clin Endocrinol. 1998; 48: 265-273.
  • 6
    Miccoli P, Minuto MN, Ugolini C, et al. Clinically unpredictable prognostic factors in the outcome of medullary thyroid cancer. Endocr Relat Cancer. 2007; 14: 1099-1105.
  • 7
    Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma. Clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000; 88: 1139-1148.
  • 8
    Byar DP, Green SB, Dor P, et al. A prognostic index for thyroid carcinoma. A study of the EORTC Thyroid Cancer Cooperative Group. Eur J Cancer. 1979; 15: 1033-1041.
  • 9
    Elisei R, Cosci B, Romei C, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab. 2008; 93: 682-687.
  • 10
    Ito Y, Yoshida H, Tomoda C. Expression of cdc25B and cdc25A in medullary thyroid carcinoma: cdc25B expression level predicts a poor prognosis. Cancer Lett. 2005; 229: 291-297.
  • 11
    Tisell LE, Oden A, Muth A, et al. The Ki67 index a prognostic marker in medullary thyroid carcinoma. Br J Cancer. 2003; 89: 2093-2097.
  • 12
    Barbet J, Campion L, Kraeber-Bodere F, et al. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2005; 90: 6077-6084.
  • 13
    Chatal JF, Campion L, Kraeber-Bodere F, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol. 2006; 24: 1705-1711.
  • 14
    Oudoux A, Salaun PY, Bournaud C, et al. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab. 2007; 92: 4590-4597.
  • 15
    Giraudet AL, Vanel D, Leboulleux S, et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab. 2007; 92: 4185-4190.
  • 16
    Mirallie E, Vuillez JP, Bardet S, et al. High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J Clin Endocrinol Metab. 2005; 90: 779-788.
  • 17
    Dromain C, de Baere T, Lumbroso J, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol. 2005; 23: 70-78.
  • 18
    Hoegerle S, Altehoefer C, Ghanem N, et al. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med. 2001; 1: 64-71.
  • 19
    Juweid ME, Hajjar G, Swayne LC, et al. Phase I/II trial of 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. Cancer. 1999; 85: 1828-1842.
  • 20
    Juweid ME, Hajjar G, Stein R, et al. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR. J Nucl Med. 2000; 41: 93-103.
  • 21
    Barbet J, Kraeber-Bodere F, Vuillez JP, et al. Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother Radiopharm. 1999; 14: 153-166.
  • 22
    De Santis R, Anastasi AM,D'Alessio et al. Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRIT). Br J Cancer. 2003; 88: 996-1003.
  • 23
    Hosono M, Hosono M, Kraeber-Bodere F, et al. Biodistribution and dosimetry study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten. J Nucl Med. 1998; 39: 1608-1613.
  • 24
    Kraeber-Bodere F, Faivre-Chauvet A, Sai-Maurel C, et al. Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft. J Nucl Med. 1999; 40: 198-204.
  • 25
    Mirallie E, Sai-Maurel C, Faivre-Chauvet A, et al. Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody. Eur J Nucl Med Mol Imaging. 2005; 32: 901-909.
  • 26
    Kraeber-Bodere F, Faivre-Chauvet A, Sai-Maurel C, et al. Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131I-labeled F(ab′)2 and pretargeted bivalent hapten and evaluation of repeated injections. Clin Cancer Res. 1999; 5: 3183s-3189s.
  • 27
    Bardies M, Bardet S, Faivre-Chauvet A, et al. Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer. J Nucl Med. 1996; 37: 1853-1859.
  • 28
    Thomas SR, Maxon MR, Kereiakes JG, et al. Quantitative external counting techniques enabling improved diagnostic and therapy decisions in patients with well-differentiated thyroid cancer. Radiology. 1977; 122: 731-737.
  • 29
    Kraeber-Bodere F, Bardet S, Hoefnagel CA, et al. Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial. Clin Cancer Res. 1999; 5: 3190s-3198s.
  • 30
    Kraeber-Bodere F, Faivre-Chauvet A, Ferrer L, et al. Pharmacokinetics and dosimetry studies for optimisation of carcinoembryonic antigen × anti-hapten bispecific antibody mediated pretargeting of iodine-131-labeled hapten in a phase I radioimmunotherapy trial. Clin Cancer Res. 2003; 9: 3973-3981.
  • 31
    Kraeber-Bodere F, Rousseau C, Bodet-Milin C, et al. Targeting, toxicity and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131-I-labeled bivalent hapten in a phase I optimisation clinical trial. J Nucl Med. 2006; 47: 247-255.
  • 32
    Shimaoka K, Schoenfeld DA, Dewwys WD, et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer. 1985; 56: 2155-2160.
  • 33
    Fromigue J, De Baere T, Baudin E, Dromain C, Leboulleux S, Schlumberger M. Chemoembolization for liver metastases from medullary thyroid carcinoma. J Clin Endocrinol Metab. 2006; 91: 2496-2499.
  • 34
    Lorenz K, Brauckhoff M, Behrmann C, et al. Selective arterial chemoembolization for hepatic metastases from medullary thyroid carcinoma. Surgery. 2005; 138: 986-993.
  • 35
    Romei C, Elisei R, Pinchera A, et al. Somatic mutations of the ret proto-oncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab. 1996; 81: 1619-1622.
  • 36
    Gross DJ, Munter G, Bitan M, et al. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer. 2006; 13: 535-540.
  • 37
    de Groot JWB, Zonnenberg BA, Quarles van Ufford-Mannesse P, et al. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab. 2007; 92: 3466-3469.
  • 38
    Frank-Raue K, Fabel M, Delorme S, Haberkorn U, Raue F. Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. Eur J Endocrinol. 2007; 157: 215-220.
  • 39
    Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008; 26: 4701-4704.
  • 40
    Kober F, Hermann M, Handler A, Krotia G. Effect of sorafenib in symptomatic metastatic medullary thyroid cancer [abstract]. J Clin Oncol. 2007; 2S: 14065.
  • 41
    Wells SA, Gosnell JE, Gagel RF, et al. Vandetinib in metastatic medullary thyroid cancer: follow-up results of an open-label phase II trial [abstract]. J Clin Oncol. 2007; 2S: 6018.
  • 42
    Schlumberger M, Carlomagno F, Baudin E, Bidart JM, Santoro M. New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab. 2008; 4: 22-32.